Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat

European Journal of Pharmacology

Volumn 343, Issue 2-3, 1998, Pages 201-207

  Kalkman, Hans O ^a   Neumann, Vroni ^a   Nozulak, Joachim ^a   Tricklebank, Mark D ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

5 HT receptor antagonist; Catalepsy; Clozapine; Receptor subtype

Indexed keywords

1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FANANSERIN; KETANSERIN; LOXAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; RECEPTOR SUBTYPE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B ANTAGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG MECHANISM; DRUG SELECTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CATALEPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0032545952     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01554-9     Document Type: Article

References (43)

1. Arnt J. Inhibitory effects on the discriminative stimulus properties of D-amphetamine by classical and newer antipsychotics do not correlate with antipsychotic activity. Relation to effects on the reward system? Psychopharmacology. 124:1996;117-125.
2. 1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties. Eur. J. Pharmacol. 304:1996;15-21.
3. Balsara J.J., Jadhav J.H., Chandokar A.G. Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology. 62:1979;67-69.
4. 1A receptors are not involved in clozapine's lack of cataleptic potential. Neuropharmacology. 35:1996;1645-1646.
5. 2-receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schizophr. Res. 15:1995;153-154.
6. 4 receptor antagonist. Trends Pharmacol. Sci. 18:1997;186-188.
7. Casey D.E. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology. 112:1993;S55-S59.
8. Coward D.M. General pharmacology of clozapine. Br. J. Psychiatry. 160 (Suppl. 17):1992;5-11.
9. Elliott P.J., Walsh D.M., Close S.P., Higgins G.A., Hayes A.G. Behavioural effects of serotonin agonists and antagonists in the rat and the marmoset. Neuropharmacology. 29:1990;949-956.
10. 1A receptor antagonists: Utility as research tools and therapeutic agents. Trends Pharmacol. Sci. 14:1993;441-448.
11. 1A receptor antagonist, WAY-100635. Eur. J. Pharmacol. 281:1995;81-88.
12. Fox S., Brotchie J. Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat. Eur. J. Pharmacol. 301:1996;27-30.
13. 2B-2C receptors in mediating fenfluramine-induced anorexia in rats. Br. J. Pharmacol. 114:1995;373P.
14. 4 receptor. Eur. J. Pharmacol. 314:1996;229-233.
15. Hicks P.B. The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci. 47:1990;1609-1615.
16. 1 recognition sites. J. Receptor Res. 8:1988;59-81.
17. 1D receptor antagonist, on brain 5-HT metabolism, extracellular 5-HT concentration and behaviour in the guinea-pig. Neuropharmacology. 34:1995;383-392.
18. Invernizzi R.W., Cervo L., Samanin R. 8-Hydroxy-2-(di-N-propylamino) tetralin, a selective serotonin 1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe medianus and dorsalis. Neuropharmacology. 27:1988;515-518.
19. Kalkman H.O., Neumann V., Tricklebank M.D. Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Naunyn-Schmiedebergs Arch. Pharmacol. 355:1997;361-364.
20. 2 antagonism and EPS benefits: Is there a causal connection? Psychopharmacology. 124:1996;35-39.
21. 2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277:1996;968-981.
22. 2C/2B receptor antagonist. Br. J. Pharmacol. 111:1994;797-802.
23. 1C receptor antagonists. Eur. J. Pharmacol. 245:1993;179-182.
24. 2 receptors. Life Sci. 28:1981;1015-1022.
25. 2 receptor binding sites Mol. Pharmacol. 21:1982;301-314.
26. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology. 131:1997;57-63.
27. 2 receptor antagonist. In vitro and ex vivo selectivity profile. Eur. J. Pharmacol. 233:1993;29-35.
28. McMillen B.A., Scott S.M., Davanzo E.A. Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J. Pharm. Pharmacol. 40:1988;885-887.
29. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. 3:1995;64-75.
30. i values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
31. 4 receptor selective antagonist. J. Pharmacol. Exp. Ther. 279:1996;1392-1403.
32. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J. Pharmacol. Exp. Ther. 265:1993;207-217.
33. 3 mediated control of dopaminergic function. Psychopharmacology. 112:1993;S60-S67.
34. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J., Shen Y., Meltzer H.Y., Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268:1994;1403-1410.
35. 1D receptors causes hypothermia in the guinea-pig. J. Psychopharmacol. 8:1994;14-21.
36. 1D receptor antagonist GR 127935 on extracellular levels of 5-HT in the guinea-pig frontal cortex as measured by microdialysis. Neuropharmacology. 34:1995;377-382.
37. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther. 266:1993;684-691.
38. Wadenberg M.L. Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390. J. Neural. Transm. 89:1992;49-59.
39. Wadenberg M.L., Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: Enhancement of antipsychotic-like effects without catalepsy. J. Neural. Transm. 83:1991;43-53.
40. 2A/C receptor agonist DOI of raclopride-induced catalepsy in the rat. Eur. J. Pharmacol. 294:1995;247-251.
41. Waldmeier P.C., Delini-Stula A.A. Serotonin-dopamine interactions in the nigrostriatal system. Eur. J. Pharmacol. 55:1979;363-373.
42. 1Dβ receptors. Eur. J. Pharmacol. 314:1996;365-372.
43. 1D subtypes. Naunyn-Schmiedebergs Arch. Pharmacol. 354:1996;226-236.